{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:44:47Z","timestamp":1777481087365,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2025,5]]},"abstract":"\n Background:<\/jats:title>\n \n The cytotoxic effect of\n 212<\/jats:sup>\n Pb on microbial growth was examined, using six microorganisms, at clinically relevant time points, to determine the potency of\n 212<\/jats:sup>\n Pb as a self-sterilizing agent in radiopharmaceuticals using [\n 212<\/jats:sup>\n Pb]Pb-DOTAMTATE.\n <\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n \n Vials of radiolabeled [\n 212<\/jats:sup>\n Pb]Pb-DOTAMTATE, nonradiolabeled DOTAMTATE, and appropriate media were inoculated with\n Bacillus spizizenii<\/jats:italic>\n ,\n Candida albicans, Clostridium sporogenes, Pseudomonas aeruginosa, Staphylococcus aureus,<\/jats:italic>\n or\n Aspergillus brasiliensis<\/jats:italic>\n . Samples from each vial type were plated onto tryptic soy agar or Sabouraud dextrose plates and allowed to grow at optimal temperature for each strain to obtain quantifiable colony forming units (CFU).\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Each microbial organism observed at least a 6 log reduction in total CFUs after 6 h of exposure to [\n 212<\/jats:sup>\n Pb]Pb-DOTAMTATE drug product vials, showing no remaining colonies as compared to the vials containing only media and drug formulation with no radiolabeled material, utilizing a low absorbed dose of no greater than 1.01 kGy. A sterility assessment of the two [\n 212<\/jats:sup>\n Pb]Pb-DOTAMTATE drug product vials containing the lowest total CFUs per vial displayed no microbial growth upon incubation for 14 d.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n \n This study suggests that\n 212<\/jats:sup>\n Pb in radiopharmaceuticals is a potent microbial cytotoxic agent with self-sterilizing properties.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1089\/cbr.2024.0208","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T11:59:42Z","timestamp":1740743982000},"page":"263-269","source":"Crossref","is-referenced-by-count":0,"title":["Microbial Cytotoxic Effect of\n 212<\/sup>\n Pb in Radiopharmaceuticals"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0654-0695","authenticated-orcid":false,"given":"Aaron T.","family":"Schatzmann","sequence":"first","affiliation":[{"name":"Orano Med, Plano, TX, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania A.","family":"Stallons","sequence":"additional","affiliation":[{"name":"Orano Med, Plano, TX, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Rivera","sequence":"additional","affiliation":[{"name":"Orano Med, Plano, TX, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quy P.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Orano Med, Plano, TX, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9my","family":"Dureau","sequence":"additional","affiliation":[{"name":"Orano Med, Bessines-sur-Gartempe, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien J.","family":"Torgue","sequence":"additional","affiliation":[{"name":"Orano Med, Plano, TX, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-805299-0.00059-2"},{"issue":"3","key":"e_1_3_5_3_2","first-page":"Doc19","article-title":"The limits of sterility assurance","volume":"3","author":"von Woedtke T","year":"2008","unstructured":"von Woedtke T, , Kramer A. The limits of sterility assurance. GMS Krankenhhyg Interdiszip, 2008; 3(3):Doc19.","journal-title":"GMS Krankenhhyg Interdiszip"},{"key":"e_1_3_5_4_2","volume-title":"Radioactive Sources: Applications and Alternative Technologies","author":"National Academies of Sciences E, and Medicine","year":"2021","unstructured":"National Academies of Sciences E, and Medicine. Radioactive Sources: Applications and Alternative Technologies. National Academies of Sciences E, and Medicine: Washington, DC; 2021."},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-3-152"},{"key":"e_1_3_5_6_2","article-title":"Sterilisation of aseptic drug by sterile filtration: Microbiology validation by microbiology challenge test","author":"Belgaid A","year":"2014","unstructured":"Belgaid A, , Benaji B, , Aadil N, et al. Sterilisation of aseptic drug by sterile filtration: Microbiology validation by microbiology challenge test. J. Chem. Pharm. Res, 2014.","journal-title":"J. Chem. Pharm. Res"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1201\/9781003163138-22"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-806X(98)00206-0"},{"issue":"3","key":"e_1_3_5_9_2","first-page":"156","article-title":"Sterility and pyrogen testing of radiopharmaceuticals","volume":"17","author":"Karesh SM","year":"1989","unstructured":"Karesh SM. Sterility and pyrogen testing of radiopharmaceuticals. Journal of Nuclear Medicine Technology, 1989; 17(3):156\u2013159.","journal-title":"Journal of Nuclear Medicine Technology"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/s18020510"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-023-00221-3"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1547-0628"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01266-13"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anucene.2006.02.004"},{"key":"e_1_3_5_15_2","unstructured":"Donn\u00e9es atomiques et nucl\u00e9aires. Available from: http:\/\/www.lnhb.fr\/accueil\/donnees-nucleaires\/donnees-nucleaires-tableau\/ [Last accessed: December19 2024]."},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1515\/rrlm-2017-0028"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1590\/1519-6984.247165"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2024.0208","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2024.0208","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2024.0208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:11:36Z","timestamp":1777385496000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2024.0208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1089\/cbr.2024.0208"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2024.0208","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}